Cited by 131Bioinformatics and Genomic NetworksChronic Obstructive Pulmonary Disease (COPD) ResearchGene expression and cancer classification

Integrative phenotyping framework (iPF): integrative clustering of multiple omics data identifies novel lung disease subphenotypes

Open access
Kim, SungHwan, Herazo-Maya, Jose D., Kang, Dongwan D., Juan-Guardela, Brenda M., Tedrow, John, Martinez, Fernando J., Sciurba, Frank C., Tseng, George C. +1 more·2015·BMC Genomics

Abstract

BACKGROUND: The increased multi-omics information on carefully phenotyped patients in studies of complex diseases requires novel methods for data integration. Unlike continuous intensity measurements from most omics data sets, phenome data contain clinical variables that are binary, ordinal and categorical. RESULTS: In this paper we introduce an integrative phenotyping framework (iPF) for disease subtype discovery. A feature topology plot was developed for effective dimension reduction and visualization of multi-omics data. The approach is free of model assumption and robust to data noises or missingness. We developed a workflow to integrate homogeneous patient clustering from different omics data in an agglomerative manner and then visualized heterogeneous clustering of pairwise omics sources. We applied the framework to two batches of lung samples obtained from patients diagnosed with chronic obstructive lung disease (COPD) or interstitial lung disease (ILD) with well-characterized clinical (phenomic) data, mRNA and microRNA expression profiles. Application of iPF to the first training batch identified clusters of patients consisting of homogenous disease phenotypes as well as clusters with intermediate disease characteristics. Analysis of the second batch revealed a similar data structure, confirming the presence of intermediate clusters. Genes in the intermediate clusters were enriched with inflammatory and immune functional annotations, suggesting that they represent mechanistically distinct disease subphenotypes that may response to immunomodulatory therapies. The iPF software package and all source codes are publicly available. CONCLUSIONS: Identification of subclusters with distinct clinical and biomolecular characteristics suggests that integration of phenomic and other omics information could lead to identification of novel mechanism-based disease sub-phenotypes.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s12864-015-2170-4

Cites

39 of 39 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Omics approaches are particularly valuable for identifying early biomarkers and disease subtypes, potentially enabling targeted intervention before irreversible damage occurs.

    “These approaches are particularly valuable for identifying early biomarkers and disease subtypes, potentially enabling targeted intervention before irreversible damage occurs [161, 162].”

    From Artificial intelligence-powered prediction of diabetic complications: from clinical data to molecular omics (2026) · cites this paper as [161]

    The Methods section describes detecting biomarkers associated with lung-disease clusters, and the Discussion says multi-omics integration may identify new subphenotypes and drug targets (page numbers unavailable). The paper does not establish that these are early biomarkers or that targeted intervention could occur before irreversible damage. (LLM, conf=0.86)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Kim, S., Herazo-Maya, J. D., Kang, D. D., Juan-Guardela, B. M., Tedrow, J., Martinez, F. J., Sciurba, F. C., Tseng, G. C., & Kaminski, N.
Affiliations
  • University of Pittsburgh (US)
  • Lawrence Berkeley National Laboratory (US)
  • Yale University (US)
Corresponding author
  • Tseng, George C.
  • Kaminski, Naftali
Venue
BMC Genomics
Published
2015-11-11
Volume
16
Issue
1
Pages
924-924
ISSN
1471-2164 (ISSN-L)
OpenAlex
W2163675951
Cited by
123
References
39
Citations by year
2026: 6 · 2025: 10 · 2024: 20 · 2023: 18 · 2022: 12 · 2021: 11 · 2020: 10 · 2019: 11 · 2018: 7 · 2017: 9 · 2016: 8 · 2013: 1
FWCI
3.48
Type
journal article
Language
en
Open access
Locations
  • BMC Genomics (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • D-Scholarship@Pitt (University of Pittsburgh) (acceptedVersion)
Funders
National Institutes of Health (U01-HL108642, RC2-HL101715)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bioinformatics and Genomic Networks
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gene expression and cancer classification
Keywords
multi-omics integration, disease subphenotypes, patient clustering, chronic obstructive pulmonary disease, interstitial lung disease, mRNA expression, microRNA expression, dimensionality reduction, agglomerative clustering, immunomodulatory therapy
MeSH terms
Algorithms, Computer Simulation, Humans, Lung Diseases, Phenotype, Cluster Analysis, Discriminant Analysis, Computational Biology, Genomics, Workflow, Molecular Sequence Annotation, Datasets as Topic

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review